Although about 18% of patients with multiple myeloma in the United States are Black, they represent only 4% of clinical trial participants. This article describes why this occurs, what the consequences are, and how this…
Daysha RobinsonOctober 24, 2022
The way that multiple myeloma cells distribute throughout the body can relate to treatment types and disease progression in various ways. Imaging can be a robust source of useful information in these cases. This article,…
Daysha RobinsonOctober 24, 2022
Although multiple myeloma cannot be cured, treatments are available to help improve symptoms and manage quality of life. However, while treatments can help control the disease, mortality remains a concern for patients with multiple myeloma…
Dr. Lauren WeinandJune 7, 2022
African Americans tend to have a higher risk of developing multiple myeloma at an earlier age and a higher risk of death than whites. While certain factors, such as socioeconomic status and access to care,…
Dr. Lauren WeinandJune 7, 2022
Multiple myeloma can affect different racial groups in different ways, especially since clinical trials are often skewed without equal representation. For example, around 20% of people affected by multiple myeloma are Black, but only 6%…
Dr. Lauren WeinandJune 6, 2022
According to the International Myeloma Foundation, there are key differences in how multiple myeloma presents in African Americans compared to people of other ethnicities. First, African Americans tend to have an earlier age of onset…
Dr. Lauren WeinandFebruary 9, 2022
Many researchers have observed a disparity in overall survival between non-Hispanic Black Americans and non-Hispanic white Americans with multiple myeloma. However, the clinical characteristics and overall survival of Hispanic Americans with the disease remain unknown.…
Dr. Lauren WeinandNovember 30, 2021
Multiple myeloma treatment has improved significantly in recent years. However, mortality early in the course of the disease is still common. This study focuses on discovering trends in early mortality. The researchers sought to better…
Dr. Lauren WeinandNovember 28, 2021
Disparities in outcomes for patients with multiple myeloma have been linked to socioeconomic barriers. This study, published in Leukemia Research, aimed to provide further insight into the nature of these disparities to ensure equitable treatment.…
Dr. Lauren WeinandNovember 27, 2021
Timeliness of treatment is an important metric for multiple myeloma treatment. This study, published in Anticancer Research, focuses on the impact of the Affordable Care Act (ACA) on initial treatment delay for patients with multiple myeloma. The…
Dr. Lauren WeinandAugust 10, 2021